Archimedes Bio-degradable Bile Duct Stent Study

Bile Leak Clinical Trial

— ABBS  

Official title:

Prospective Observational Cohort Study: To Assess the Utility of Bio-degradable Bile Duct Stent in the Drainage of Bile Duct.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04477005
• Other study ID #: 20GA041
• Status: Completed
• Start date: November 11, 2020
• Est. completion date: August 2, 2023

Study information

• Verified date: August 2023
• Source: Nottingham University Hospitals NHS Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective observational cohort study to assess the utility of bio-degradable bile duct stent in the drainage of bile duct. All consecutive patients who will undergo ERCP procedure for bile leaks and patients with bile duct stones and intact gall bladder will be recruited to the study. The planned sample size is 53 and patients will be followed up for 180 days. The primary objective is to assess the utility of biodegradable bile duct plastic stents in the drainage of bile duct. The secondary Secondary objectives are To assess 1. Technical success of biodegradable stents 2. Complications 3. Patient related cost savings (Time off work, travel time for the patient) 4. Hospital related cost savings (Repeat procedure costs, follow up appointments)

Description:

This is a Multi-centre prospective observational cohort study assessing biodegradable stents in the drainage of bile duct. The participating organisations are Nottingham university hospitals NHS trust which is the host and sponsor of this study, University college London Hospitals NHS foundation trust and Leeds teaching hospitals NHS trust. The population studied will be patients who need temporary bile duct stent insertion for bile leak and patients who had ERCP for removal of CBD stones and have stones either in the neck of gall bladder or cystic duct and awaiting cholecystectomy. These are the group of patients who may not benefit from a repeat endoscopic procedure to remove the stent. As the target population is rare, all consecutive patients with above condition will be recruited to the study. All patients who are referred for ERCP will be screened to see if they meet the eligibility criteria to participate in the study. The patient information sheet (PIS) will be sent to the patient along with the endoscopy appointment. The pateints will be consented both for the procedure and the study on the day of the procedure. Then the patients will have the procedure in their respective endoscopic units. All ERCP procedures will be done either by an accredited endoscopist or by a trainee under the close supervision of the accredited endoscopist. Once the patients have their treatment, the patients will be observed for four hours for complications. Then discharged home if they are well and do not have any symptoms such as pain, persistent low blood pressure (defined as systolic less than 100) and have recovered from the effects of sedation. If at all the pateints develop any of the above symptoms, then the patients will be admitted for an overnight observation. The patients will have a telephone consultation by research specialist nurses the next day to assess if they have symptoms such as abdominal pain, vomiting, vomiting of blood and dark tarry stools. If the patients develop any of these symptoms, the patients will be assessed in the bio-medical research centre or respective inpatient facility in relevant centres. The patients will then have a blood test including full blood count, liver function and renal function. Amylase will be done only if they complain of abdominal pain as a proportion of patients will have hyper-amylasaemia following ERCP. The patients will also receive a telephone consultation (Research nurse) on day 7 post procedure to assess if they have any of the above symptoms. A quality of life questionnaire will be completed at this stage. The investigators will be using slow degrading stents so, therefore the patients will have an abdominal x-ray 90 days after the procedure and if the stent is not visible on abdominal X-ray then they would have completed the study. As recent studies have shown that the stent appear partially degraded in some patients, if the stent is visible on x-ray then the patients will have one more follow up visit with an abdominal x-ray at 180 days. The invetstigator will not remove the stent as the stent would have partially degraded and would have lost its tensile strength. Almost all bile leaks are inpatients so the resolution of bile leak will be assessed while they are inpatients. The resolution of bile leak is defined as no output from the external drain that was inserted through the skin under radiological guidance. For bile duct stones it is the prevention of bile duct infection (Cholangitis). The pateints will have telephone consultations on days 1,30,60,90 and 180 to asses if they have symptoms such as abdominal pain, jaundice. A quality of life questionnaire (EQ-5D-5L) will be completed at all these visits. Once the patient completes all of the above, they will have completed the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: August 2, 2023
• Est. primary completion date: September 23, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• • Participant is willing and able to give informed consent for participation in the study.
• Male or Female, aged 18 years or above.
• Patients who have an indication for ERCP.
• Patients who have bile leak either post cholecystectomy or liver resection.
• Patients who are on the waiting list for cholecystectomy for gall stones but have bile duct stones and listed for removal of bile duct stones.
• Able (in the Investigators opinion) and willing to comply with all study requirements.
• Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.

Exclusion Criteria:

• Female participants who is pregnant, lactating or planning pregnancy during the course of the study.
• Patients who are unable to consent for the study.
• Participant who is terminally ill
• Patients who come for ERCP and routine stent change
• Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

Related Conditions & MeSH terms

• Bile Leak
• Cholecystitis
• Common Bile Duct Stone With Chronic Cholecystitis

Intervention

Device:
• ERCP and insertion ofBio-degradable bile duct stent
ERCP is an accepted mode of treatment and patients rarely need surgery for bile leaks and bile duct stents. Endoscopic management involves sphincterotomy (cutting open the Sphincter of Oddi) and insertion of a plastic or metal stent. Instead of placing a plastic stent bio-degradable stent will be placed. They will be followed up on Day 1, 7,30, 60,90 and 180 days. they will have abdominal x-ray on day 90 and day180.

Locations

Country	Name	City	State
United Kingdom	Nottingham University Hospitals NHS Trust	Nottingham

Sponsors (1)

Lead Sponsor	Collaborator
Nottingham University Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resolution of bile leak	In patients who have bile leak post HPB surgery, They will have an external drain to drain the leaked bile. Resolution of bile leak is defined as no output of bile through the external drain.	180 days
Primary	Incidence of cholangitis in patients who had ERCP for bile duct stones and are awaiting gall bladder removal.	Cholangitis- infection of bile duct ( fever, rigors, elevated white cell count and CRP). Incidence of cholangitis post procedure will be reported.	180 days